The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Thalassemia Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Long-term results of the BELIEVE study: luspatercept in patients with beta-thalassemia
Maria Domenica Cappellini, MD, University of Milan, Milan, Italy, shares some long-term results from the Phase III BELIEVE study (NCT02604433) evaluating the safety and efficacy of luspatercept in patients with transfusion-dependent beta-thalassemia. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Member of the advisory board for Celgene and BMS
